292 related articles for article (PubMed ID: 10372792)
1. Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture.
Freedland CS; Mansbach RS
Drug Alcohol Depend; 1999 May; 54(3):183-94. PubMed ID: 10372792
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
3. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay.
Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A
Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498
[TBL] [Abstract][Full Text] [Related]
4. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
5. Immunological Modulation and Control of Parasitaemia by Ayahuasca Compounds: Therapeutic Potential for Chagas's Disease.
Katchborian-Neto A; Santos MFC; Vilas-Boas DF; Dos Santos EG; Veloso MP; Bueno PCP; Caldas IS; Soares MG; Dias DF; Chagas-Paula DA
Chem Biodivers; 2022 Oct; 19(10):e202200409. PubMed ID: 36163588
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
7. Biodiversity of β-Carboline Profile of
Santos BWL; Oliveira RC; Sonsin-Oliveira J; Fagg CW; Barbosa JBF; Caldas ED
Plants (Basel); 2020 Jul; 9(7):. PubMed ID: 32660098
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological interaction of compounds in ayahuasca: a systematic review.
Ruffell S; Netzband N; Bird C; Young AH; Juruena MF
Braz J Psychiatry; 2020; 42(6):646-656. PubMed ID: 32638916
[TBL] [Abstract][Full Text] [Related]
9. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.
Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A
Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972
[TBL] [Abstract][Full Text] [Related]
10. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
[TBL] [Abstract][Full Text] [Related]
11. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage.
Pires AP; De Oliveira CD; Moura S; Dörr FA; Silva WA; Yonamine M
Phytochem Anal; 2009; 20(2):149-53. PubMed ID: 19140116
[TBL] [Abstract][Full Text] [Related]
12. Chemical Composition of Traditional and Analog Ayahuasca.
Kaasik H; Souza RCZ; Zandonadi FS; Tófoli LF; Sussulini A
J Psychoactive Drugs; 2021; 53(1):65-75. PubMed ID: 32896230
[TBL] [Abstract][Full Text] [Related]
13. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
14. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
[TBL] [Abstract][Full Text] [Related]
15. Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity.
Gianfratti B; Tabach R; Sakalem ME; Stessuk T; Maia LO; Carlini EA
J Ethnopharmacol; 2022 Mar; 285():114865. PubMed ID: 34822961
[TBL] [Abstract][Full Text] [Related]
16. Basics of the medical use of ayahuasca: physiology of dimethyltryptamine.
Ede F; Attila K; Attila S; Csaba F; Csaba M
Lege Artis Med; 2016; 26(9-10):413. PubMed ID: 29537778
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies.
Dos Santos RG; Hallak JE
J Psychoactive Drugs; 2017; 49(1):1-10. PubMed ID: 27918874
[TBL] [Abstract][Full Text] [Related]
18. Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca.
Berlowitz I; Egger K; Cumming P
Front Pharmacol; 2022; 13():886408. PubMed ID: 35600851
[TBL] [Abstract][Full Text] [Related]
19. Ayahuasca: What Healthcare Providers Need to Know.
Goldin D; Salani D
J Addict Nurs; 2021 Apr-Jun 01; 32(2):167-173. PubMed ID: 34060770
[TBL] [Abstract][Full Text] [Related]
20. New Insights into the Chemical Composition of Ayahuasca.
Rodríguez L; López A; Moyna G; Seoane GA; Davyt D; Vázquez Á; Hernández G; Carrera I
ACS Omega; 2022 Apr; 7(14):12307-12317. PubMed ID: 35449956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
